Alpha Teknova Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $43.7M+15.8% YoYTTM through 30 Jun 2026
Net Income -$16.8MTTM through 30 Jun 2026
Free Cash Flow -$7.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 33.2% |
| EBITDA Margin | -21.7% |
| Operating Margin | -41.9% |
| Net Margin | -38.4% |
Returns
-25.1%ROE
-16.7%ROA
Balance Sheet Health
Debt / Equity0.19x
Current Ratio4.58x
Net Debt-$8.2Mnet cash position
Cash & Equivalents$6M
Quality Metrics
Altman Z-Score6.60
Piotroski F-Score4 / 9
FCF Margin-16.8%
Rule of 40-16.5
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $40.5M
Diluted EPS-$0.31TTMFY2025: $-0.32
Dividend
No dividend
Capital Allocation
R&D Spend$2.2M
Capex Intensity2.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Lab Essentials | $31M | +7.3% | |
| Clinical Solutions | $7.7M | +8.5% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.